TY - JOUR
T1 - Recent trends in antibody-based oncologic imaging
AU - Kaur, Sukhwinder
AU - Venktaraman, Ganesh
AU - Jain, Maneesh
AU - Senapati, Shantibhusan
AU - Garg, Pradeep K.
AU - Batra, Surinder K.
N1 - Funding Information:
We thank Kristi L. Berger for editing the manuscript. The authors on this work are supported, in part, by grants from the US Department of Defense (BC074631 and PC074289) and the National Institutes of Health (R21 CA156037, RO1 CA78590, UO1 CA111294, RO1 CA131944, RO1 CA133774, RO1 CA138791, RO3 CA 139285 and P50 CA127297).
PY - 2012/2/28
Y1 - 2012/2/28
N2 - Antibodies, with their unmatched ability for selective binding to any target, are considered as potentially the most specific probes for imaging. Their clinical utility, however, has been limited chiefly due to their slow clearance from the circulation, longer retention in non-targeted tissues and the extensive optimization required for each antibody-tracer. The development of newer contrast agents, combined with improved conjugation strategies and novel engineered forms of antibodies (diabodies, minibodies, single chain variable fragments, and nanobodies), have triggered a new wave of antibody-based imaging approaches. Apart from their conventional use with nuclear imaging probes, antibodies and their modified forms are increasingly being employed with non-radioisotopic contrast agents (MRI and ultrasound) as well as newer imaging modalities, such as quantum dots, near infra red (NIR) probes, nanoshells and surface enhanced Raman spectroscopy (SERS). The review article discusses new developments in the usage of antibodies and their modified forms in conjunction with probes of various imaging modalities such as nuclear imaging, optical imaging, ultrasound, MRI, SERS and nanoshells in preclinical and clinical studies on the diagnosis, prognosis and therapeutic responses of cancer.
AB - Antibodies, with their unmatched ability for selective binding to any target, are considered as potentially the most specific probes for imaging. Their clinical utility, however, has been limited chiefly due to their slow clearance from the circulation, longer retention in non-targeted tissues and the extensive optimization required for each antibody-tracer. The development of newer contrast agents, combined with improved conjugation strategies and novel engineered forms of antibodies (diabodies, minibodies, single chain variable fragments, and nanobodies), have triggered a new wave of antibody-based imaging approaches. Apart from their conventional use with nuclear imaging probes, antibodies and their modified forms are increasingly being employed with non-radioisotopic contrast agents (MRI and ultrasound) as well as newer imaging modalities, such as quantum dots, near infra red (NIR) probes, nanoshells and surface enhanced Raman spectroscopy (SERS). The review article discusses new developments in the usage of antibodies and their modified forms in conjunction with probes of various imaging modalities such as nuclear imaging, optical imaging, ultrasound, MRI, SERS and nanoshells in preclinical and clinical studies on the diagnosis, prognosis and therapeutic responses of cancer.
KW - Antibody
KW - Imaging
KW - Optical
KW - SPECT
KW - Tumor
UR - http://www.scopus.com/inward/record.url?scp=84355162011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84355162011&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2011.10.017
DO - 10.1016/j.canlet.2011.10.017
M3 - Review article
C2 - 22104729
AN - SCOPUS:84355162011
VL - 315
SP - 97
EP - 111
JO - Cancer Letters
JF - Cancer Letters
SN - 0304-3835
IS - 2
ER -